Hospira — Investor Day (September 2011)
131 slides from Hospira's investor day presentation, Sep 7, 2011
Slide 1: Hospira 2011 Investor Day
1 World’s Leading Provider of Injectable Drugs and Infusion Technologies Hospira 2011 Investor Day September 7, 2011 Lake Forest, Illinois
Slide 2: Agenda
Agenda Break Sumant Ramachandra & Anil D’Souza Pipeline and Products Event Adjourns; Shuttle Departs 3:00 p.m. Mike Ball & Presenters Q&A Tom Werner Financial Strategy Jim Hardy Operational Excellence . Lunch with Hospira Management 12:00 p.m. Tim Oldham & Ron Squarer - APAC Svend Andersen & Paul Gr
Slide 3: Housekeeping Items
Housekeeping Items Handouts Electronics Restrooms Q&A Transportation Safety
Slide 4: Safe Harbor
Safe Harbor This event contains forward-looking statements within the meaning of the federal securities laws. Hospira intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements in the federal securities laws. In some cases, you can identify th
Slide 5: Mike Ball, Chief Executive Officer
1 World’s Leading Provider of Injectable Drugs and Infusion Technologies Mike Ball Chief Executive Officer
Slide 6: Investor Day Objectives
2 Investor Day Objectives Deepen relationship with management Discuss key growth drivers and strategy Provide 2016 financial goals Answer questions
Slide 7: What Differentiates Hospira (Why I Came)
3 What Differentiates Hospira (Why I Came) US-centric company with tremendous international opportunities Channel strength and share gives customer-centric opportunity for differentiation High probability of success and short-cycle-time generic R&D model with good pipeline Barriers to entry Company
Slide 8: Around the World in Days
4 Around the World in 150 Days Toronto 4/14, 7/12 Wisconsin 4/6 Los Angeles 6/9 NYC 5/4 Boulder 5/5 San Diego 5/19 Chicago 3/30 Rocky Mount 8/12 Leamington Spa 7/5, 6/6 Paris 7/7 Singapore 5/29 Tokyo 6/3 Osaka 6/2 Seoul 6/30 Melbourne 6/29 Ahmedabad 8/25 Chennai 8/23 Vizag 8/20
Slide 9: My Learnings
5 My Learnings Past 150 days Hospira’s biggest opportunities and challenges Key areas of focus Strength of management team
Slide 10: Key Questions We Will Address Today
6 Key Questions We Will Address Today With the large Paragraph IVs launched, what kind of growth can we expect to see from Hospira’s core SIP business? How can Hospira profitably compete in biosimilars? How does Hospira accelerate growth outside the US and what is the margin potential in these regio
Slide 11: Hospira's Investment Thesis
7 Hospira’s Investment Thesis We are riding the wave of healthcare megatrends 1 We are best positioned to capture share 3 The global market opportunity for Hospira is huge 2
Slide 12: Healthcare Megatrends Play to Our Strengths
8 8 Healthcare Megatrends Play to Our Strengths Aging population Rising costs Increased access To reduce costs medication errors infection To improve patient safety caregiver safety productivity Improved outcomes Trends Our Strengths
Slide 13: Aging Populations: Healthcare Costs Growing
0 10 20 30 40 50 60 70 80 90 95+ 0 5 10 15 20 9 1. Aging Populations: Average Expenditures Growing EU Healthcare Costs for Patients 65+ are Increasing Significantly Average per Capita Expenditure in EU as Percentage of Per Capita GDP (%) Age (Years) And the US faces a similar situation with aging Ba
Slide 14: Healthcare Spend: Burdening Global Economy
10 2. Healthcare Spend: Burdening Global Economy Source: PwC Health Research Institute 2010. US Healthcare Spend as a % of GDP is Increasing Significantly US Healthcare Expenditures as a % of GDP 0% 5% 10% 15% 20% 25% 2000 2010 2020
Slide 15: Increased Access: Emerging Markets
11 3. Increased Access: Emerging Markets Source: PwC Health Research Institute 2010. % Growth in GDP, Health Spending 2010-2020 GDP growth Health spending growth As emerging countries’ standards of living grow, demand for healthcare is on the increase This decade will see significant upward mobility
Slide 16: Need to Improve Outcomes: Serious Hospital Issue
12 4. Need to Improve Outcomes: Serious Hospital Issue Number of people harmed each year by medication errors in US1 1.5M Excess healthcare costs incurred by hospital-acquired infections (HAI) in US a year3 ~ $30B Estimated economic burden caused by medication errors in US every year2 $77B Institute
Slide 17: Hospira's Investment Thesis
13 We are riding the wave of healthcare megatrends 1 The global market opportunity for Hospira is huge 2 We are best positioned to capture share 3 Hospira’s Investment Thesis
Slide 18: Long Growth Runway: Multiple Growth Drivers
14 Long Growth Runway for Hospira – Multiple Growth Drivers 2. Products losing market exclusivity 1. Existing SIP market growth 3. Medication Management growth 5. Biosimilars 4. Global portfolio expansion 14
Slide 19: Tremendous Opportunity in Markets Outside the US
16 Tremendous Opportunity in Markets Outside the US Source: Hospira, July 2011. Hospira SIP Marketed Molecules by Country Number of On-market Generic Molecules 0 140 20 40 60 80 100 120
Slide 20: Tremendous Opportunity in Markets Outside the US
17 Tremendous Opportunity in Markets Outside the US Source: Hospira, July 2011. Hospira SIP Marketed Molecules by Country Number of On-market Generic Molecules 0 140 20 40 60 80 100 120 Spain +59 Germany +68 Italy +42 UK +46 France +66 Additional molecules +
Slide 21: Increase Available Market by Qualifying Products in More Countries
18 We Can Increase the Available Market by Qualifying Our On-Market Products in More Countries Hospira +$5B $12B Additional opportunity for existing products in our current footprint: +$5B Source: IMS 2010; Hospira analysis. Opportunity represented by launching Hospira on-market generic injectable p
Slide 22: Tapping into the Emerging Market Opportunity
20 And by Tapping into the Emerging Market Opportunity Hospira +$5B +$5B +$6B $12B Emerging market opportunity: +$5B Source: IMS 2010; Hospira analysis; emerging market data derived from Datamonitor report on injectables for BRIC countries and IMS for rest of world.
Slide 23: Opportunity to Increase Participation in Generic Injectable Market
21 Hospira has Tremendous Opportunity to Increase Our Participation in the Generic Injectable Market Current Hospira Hospira’s potential share +$5B +$5B +$6B $12B Total market size: $28B Additional opportunity for existing products in our current footprint: +$5B Additional generic opportunity in exi
Slide 24: Generics Remain Underutilized Around the Globe
22 Generics Remain Underutilized Around the Globe Megatrends will drive increased generic utilization 0 20 40 60 80 100 Source: IMS Health, Midas, Market segmentation, June 2009; Prescription-only generics. % Generic Market Share (units) U.S. Canada Germany Poland UK Brazil Czech France Turkey Austr
Slide 25: Generics Remain Underutilized Around the Globe
23 Generics Remain Underutilized Around the Globe Megatrends will drive increased generic utilization 0 20 40 60 80 100 Generic penetration opportunity: +$2B Source: IMS Health, Midas, Market segmentation, June 2009; Prescription-only generics. % Generic Market Share (units)
Slide 26: Global SIP Objective
24 Global SIP Objective #1 generic injectable provider in every major market we serve
Slide 27: Biosimilars Present Another Growth Opportunity
25 Biosimilars Present Another Compelling Growth Opportunity Source: Hospira analysis of Datamonitor IMS data, Dec. 2010; excludes vaccines. Global Biologics Total $116B; Growing at 6.3% Per Year Europe $29.9B Japan $8.5B US $53.1B Rest of World $24.6B
Slide 28: Focusing on Key Biologic Therapeutic Areas
26 Hospira is Focusing on Key Biologic Therapeutic Areas Disease Group1 2010 Sales2 ($B) Immunology & Inflammation $28.8 Oncology $25.5 Diabetes $15.6 Multiple Sclerosis $9.6 Erythropoiesis-Stimulating Agent $8.5 Others $27.7 Industry Biologics Opportunity by Therapeutic Area Source: Hospira analysi
Slide 29: Medication Management Opportunities With IV Clinical Integration
27 Medication Management Also Has Opportunities With IV Clinical Integration as the Future of MMS IV Clinical Integration forecast to grow US MMS market by ~$400M by 2016 IV Clinical Integration (IVCI): a closed-loop system linking the IV pump, physician order, patient and patient record Future diff
Slide 30: Emerging Markets Opportunities for Medication Management
28 Current Situation And Emerging Markets Offer Opportunities for Medication Management Large number of gravity infusions in developing world Examples: China: 1.5B Brazil: 151M Gravity infusions do not meet infusion pump precision levels Opportunity Heavy reliance on gravity infusions results in nee
Slide 31: Hospira's Investment Thesis
29 Hospira’s Investment Thesis We are riding the wave of healthcare megatrends 1 The global market opportunity for Hospira is huge 2 We are best positioned to capture share 3
Slide 32: Channel Strength: Grow Generic Injectable Leadership Position
30 Source: IMS 2010; Hospira analysis. Market share in units represents the market of genericized products in which Hospira participates. Global Generic Injectable Market (Units) Market of generic injectables in which Hospira participates Invest R&D dollars to expand global portfolio Differentiate t
Slide 33: Channel Strength: Drive Medication Management Penetration
31 Source: 2010 MDI, IMS Hospital Supply Index, Millennium Research Group, other syndicated and company reports; internal analysis. Market includes hospital and alternate site channels and BRIC countries. MMS (Medication Management Systems) is part of Medication Management, which also includes gravi
Slide 34: End-to-End Solution Increases Utilization
32 Offering an End-to-End Solution Increases Utilization +6% revenue +20% revenue +20% Total additional revenue lift to SIP & differentiated delivery revenue when selling Hospira solutions and pumps Source: Hospira regression analysis. SIP alone represents an account that does not purchase Hospira s
Slide 35: World's Leading Provider of Injectable Drugs and Infusion Technologies
33 33 We are the World’s Leading Provider of Injectable Drugs and Infusion Technologies SIP MMS Biosimilars Consumables Solutions US Global US Global OUS Global US OUS Hospira Fresenius Teva Sandoz Baxter CareFusion B. Braun ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü Hospi
Slide 36: Leverage Our Infrastructure
34 Leverage Our Infrastructure Increase volume across the enterprise Improve efficiency through LEAN manufacturing Ensure high-quality, low-cost manufacturing Leveraging Infrastructure not only Supports Revenue Growth but also Drives Margin Expansion
Slide 37: Vizag, India Facility
35 Approximately a 1.1M square-foot facility Capability for both terminal sterilization and aseptic processing More than 50 molecules across vials, Carpuject™ and ampoules Total capacity of over 500M vials per year Vizag, India Facility: Building Significant Capacity for Future Growth
Slide 38: Employee Engagement
Employee Engagement Strategy crystal clear and understood Aligned Team - not silos Nimble - quick decision making Accountability and responsibility Relentless execution Results oriented Laser focus on the MAIN THING
Slide 39: Vision for 2015+ Across Three Time Horizons
37 Focus on high-quality manufacturing Remediate MMS Invest in global SIP International penetration with tuck-in acquisitions Continued biosimilar launches OUS New product launches Recapture US share for select molecules Enhance customer-centricity We are Accomplishing our Vision for 2015+ Across Th
Slide 40: Our Mandate is Clear
38 Our Mandate is Clear Hospira is the World’s Leading Provider of Injectable Drugs and Infusion Technologies
Slide 41: Portfolio of Products
1 Portfolio of Products Sumant Ramachandra and Anil D’Souza
Slide 42: Agenda
2 Agenda Small-molecule generics Small-molecule pipeline Biosimilars Proprietary pharma Medication management and IV clinical integration Contract manufacturing
Slide 43: Multi-Faceted Strategy to Grow Small-Molecule Generic Injectables
3 A Multi-Faceted Strategy to Grow Our Small-Molecule Generic Injectables Portfolio 1. Originator products losing market exclusivity 2. IP strategies 3. Portfolio expansion 4. Differentiated delivery systems
Slide 44: Originator Products Losing Market Exclusivity
4 1. Originator Products Losing Market Exclusivity: Market Landscape Remains Attractive * Local Market Value (LMV) refers to IMS July 2010 moving annual total (MAT) sales of equivalent products already being sold in market, whether patented or generic. LMV is not a forecast of Hospira’s expected net
Slide 45: Leveraging IP Strategies to Maximize Return and Minimize Risk
5 2. Leveraging IP Strategies to Maximize Return and Minimize Risk IP Strategy Upside Downside Hospira Success Litigation leader Hospira takes active steps, including litigation to establish a first-to-market position Potential duopoly position with the originator Hospira assumes all the litigation
Slide 46: Portfolio Expansion
6 3. Portfolio Expansion: Developing Products to Increase Participation in the Generic Injectable Market Current Hospira Hospira’s potential share +$5B +$5B +$6B $12B Total market size: $28B Additional opportunity for existing products in our current footprint: +$5B Additional generic opportunity in
Slide 47: Differentiated Delivery Systems
7 4. Differentiated Delivery Systems: Support a Competitive Leadership Position Hospira is constantly evaluating unmet customer needs to enhance and expand its differentiated drug delivery portfolio ADD- Vantage™ VisIV™ Flex Bags iSecure™ Syringe Patient Safety Caregiver Safety Workflow Productivity
Slide 48: Agenda
8 Agenda Small-molecule generics Small-molecule pipeline Biosimilars Proprietary pharma Medication management and IV clinical integration Contract manufacturing
Slide 49: Pipeline Update: Small-Molecule Injectables
9 Pipeline Update: Small-Molecule Injectables PREVIOUS Reporting Methodology 20 25 Submitted for regulatory approval LMV*: $3.6B 45 Molecules with LMV* of $11B * LMV (local market value) refers to IMS 2010 sales of equivalent products already being sold in market, whether patented or generic. LMV is
Slide 50: Pipeline Update: New Reporting Methodology
10 * LMV (local market value) refers to IMS 2010 sales of equivalent products already being sold in market, whether patented or generic. LMV is not a forecast of Hospira’s expected net sales. 55 32 28 APAC EMEA Americas Includes additional countries beyond the previous methodology Better reflects Ho
Slide 51: Timing of Pipeline Launches
11 Timing of Pipeline Launches: 71% of Hospira’s Overall $16B LMV* Pipeline Launching Over the Next Five Years Small-Molecule Generic Pipeline Based Upon Planned Launch Year Source: IMS 2010, Hospira analysis. 2H 2011 2013 2014 2015 2016 2012 2017+ (Local Market Value*) *Local market value refers to
Slide 52: Pipeline of New-to-Country Launches
12 Hospira’s Pipeline of New-to-Country Launches with LMV* of $16B Currently Targeting 623 New Country Launches APAC 77 Americas 71 EMEA 475 *Local market value refers to 2010 annual sales of equivalent products already being sold in the market, whether patented or generic. Local market value is not
Slide 53: Pipeline Focused on Key Therapeutic Areas
13 The Pipeline is Focused on Key Therapeutic Areas * LMV (local market value) refers to 2010 annual sales of equivalent products already being sold in the market, whether patented or generic. LMV is not a forecast of Hospira’s expected net sales. Source: IMS 2010; Hospira analysis. Hospira’s small
Slide 54: Agenda
14 Agenda Small-molecule generics Small-molecule pipeline Biosimilars Proprietary pharma Medication management and IV clinical integration Contract manufacturing
Slide 55: Well Positioned for Emerging Profile of Biosimilars
15 Hospira Well Positioned to Deal with Emerging Profile of Biosimilars Source: FTC Report June 2009; Hospira internal analysis Probability of success Cost Time Product op. profit margins Barriers to entry Point of differentiation Competitors Decision makers Marketing investment Pricing Biosimilars
Slide 56: Capabilities to Develop, Manufacture and Commercialize Biosimilars
16 Hospira has the Capabilities to Develop, Manufacture and Commercialize Biosimilars Research and Bioprocess Microbial and mammalian cell line development EMA approved cell culture processes mAb process development and scale-up Pegylation process development and scale-up Clinical, Regulatory and IP
Slide 57: Global Biosimilar Legal and Regulatory Environment
17 The Global Biosimiliar Legal and Regulatory Environment is Evolving 2009 2011 2000-2004 2008 Canada Australia Europe Japan United States (established legal pathway) Europe (mAb draft) 2010 Biosimilars have Advanced in All Key Regulated Markets FDA and EMA are exploring areas for collaboration in
Slide 58: Commercial Inroads with Retacrit and Nivestim
18 Hospira has Already Made Significant Commercial Inroads with Retacrit™ and Nivestim™ Retacrit (short-acting EPO): EU approved in December 2007 Expanding to Central and Eastern Europe Retacrit is the #1 EPO biosimilar in EMEA Biosimilars have 18% of the EU EPO market Retacrit ~50% EPO Biosimilar M
Slide 59: Preparing for Market Formation in US
19 We are Preparing for Market Formation in US Key decision makers in the US perceive biosimilars to be more similar to a brand than to a generic, at least in the initial years Biosimilars will require a certain level of clinical detailing to decision makers; activities to address the range of stake
Slide 60: One of the Industry's Largest Biosimilar Pipelines
20 Hospira has One of the Industry’s Largest Biosimilar Pipelines * LMV (local market value) refers to 2010 annual sales of equivalent products already being sold in the market, whether patented or generic. LMV is not a forecast of Hospira’s expected net sales. LMV Source: IMS 2010; Hospira, Celltri
Slide 61: Achieving Significant R&D Milestones
21 Achieving Significant R&D Milestones EPO Successfully completed Phase I US Phase III starts in Q4 2011 Filgrastim Approval in Australia Pre-IND meeting with FDA Improved label to include 7 day out of fridge Pegfilgrastim Optimized process and formulation mAb 1 Global clinical pathway Phase I star
Slide 62: Capturing the Biosimilar Opportunity
22 Hospira is Capturing the Biosimilar Opportunity with Retacrit™ and Nivestim™ Hospira is planning to commercialize our biosimilars Retacrit and/or Nivestim in up to 49 countries
Slide 63: Pipeline Will Allow Us to Market Biosimilars Across the Globe
24 Hospira’s Pipeline Will Allow Us to Market Biosimilars Across the Globe
Slide 64: Agenda
25 Agenda Small-molecule generics Small-molecule pipeline Biosimilars Proprietary pharma Medication management and IV clinical integration Contract manufacturing
Slide 65: Precedex Cornerstone of Proprietary Pharma Strategy
26 Precedex™ Forms the Cornerstone of Hospira’s Proprietary Pharma Strategy Established Precedex as a leading injectable sedation agent in US Additional submissions forthcoming to support long-term indication (>24 hours) and pediatric use Exploring opportunities to extend franchise beyond current pa
Slide 66: Posidur and Dyloject Leverage Precedex Platform
27 Posidur™ and Dyloject™ Will Leverage Our Precedex™ Platform Late-stage pipeline products designed to capitalize on acute-care channel strength built over past decade with Precedex Experienced US sales force with strong physician relationships and direct coverage across top-quartile hospitals Posi
Slide 67: Agenda
28 Agenda Small-molecule generics Small-molecule pipeline Biosimilars Proprietary pharma Medication management and IV clinical integration Contract manufacturing
Slide 68: Global Leader in Medication Management Systems
29 29 Global Devices (MMS) (Units) Global MMS market value (2010): $2.8B Hospira’s MMS portfolio (2010): $0.6B ~21% market share ($) Growing OUS portfolio Serve both hospital and alternate site channels Hospira is a Global Leader in Medication Management Systems with Room to Grow Hospira holds a lea
Slide 69: MMS is Key to Our Portfolio Strategy
30 And MMS is Key to Our Portfolio Strategy MMS is synergistic with the rest of our portfolio Differentiates us versus other manufacturers of generic SIP Each pump sale associated with greater than $1,700 in annual pull-through revenue will grow further as IV clinical integration increases software
Slide 70: IV Clinical Integration: Next-Wave Opportunity
31 IV Clinical Integration (IVCI): Next-Wave Opportunity Facilitates seamless communication between hospital EMR systems, pumps and other devices Connects the pump, order, patient and record Customer demand is building Supporting technology in place in most hospitals IVCI Supports Improved Patient O
Slide 71: Clinical Integration: Early Results are Promising
32 Clinical Integration: Early Results are Promising 60% reduction in reported heparin administration errors1 Safer Nursing time to program pumps reduced 25%1 Efficient $6M-$10M saved annually2 by preventing adverse drug events3 Fiscal R Paoletti and A Prusch, Advancing Smart Pump Safety with IV Int
Slide 72: TheraDoc Addressing Significant Customer Need
33 TheraDoc™ Addressing Significant Customer Need Key Market Trends / Plans Real-time clinical surveillance with embedded knowledge to improve clinical workflow and decisions Increase in regulatory pressures on quality / performance metrics alerting / intervention tools demanded Increase in global t
Slide 73: Emerging Markets Offer Opportunities for Medication Management
34 Current Situation Emerging Markets Offer Opportunities for Medication Management Large number of gravity infusions in developing world Examples: China: 1.5B Brazil: 151M Gravity infusions do not meet infusion pump precision levels Opportunity Heavy reliance on gravity infusions results in need fo
Slide 74: Agenda
35 Agenda Small-molecule generics Small-molecule pipeline Biosimilars Proprietary pharma Medication management and IV clinical integration Contract manufacturing
Slide 75: Contract Manufacturing - One2One
36 Contract Manufacturing – Hospira’s One2One™ A good business for Hospira with significant growth opportunities Hospira’s 2011-2016 projected CAGR: low teens, above market growth Provides cost-effective manufacturing solutions to global pharma and biotech companies Leveraging Hospira’s strong reput
Slide 76: In Summary: Driving Growth Through Focused Product Strategies
37 IN SUMMARY We are Driving Growth Through Our Focused Product Strategies The market opportunity for generic injectables is large We are well positioned with our multi-pronged strategy to capture share We are at the forefront of biosimilars and preparing for market formation in the US We are drivin
Slide 77: Hospira - Regional Strategy
1 Hospira – Regional Strategy September 7, 2011
Slide 78: Agenda
2 Agenda Americas EMEA APAC
Slide 79: Americas At-A-Glance
Americas At-A-Glance 3 Growth Drivers SIP portfolio expansion Biosimilars Dyloject™ Posidur™ Differentiated delivery systems Clinical integration in MMS Key Products Docetaxel Precedex™ Symbiq™ Heparin Vancomycin Plum A+™ Hydromorphone ADD-Vantage™ MedNet™ Meropenem iSecure™ VisIV™ 2010 Sales: $3.1B
Slide 80: Strategy: US
4 Strategy: US Expand #1 generic injectables leadership position Maximize new product launches leveraging differentiated offerings Target on-market generics not in current Hospira portfolio Generic Injectables Medication Management Clinical Integration Biosimilars Proprietary Reintroduce Symbiq™ to
Slide 81: Strategy: Canada & Latin America
5 Strategy: Canada & Latin America Extend SIP leadership with enhanced pipeline launches and differentiated delivery systems Establish MMS technology leadership position Drive Precedex™ growth, leveraging enhanced sales and marketing Canada LATAM Biosimilars Proprietary Other key Initiatives Grow Br
Slide 82: Brazil: Unlocking Potential Growth Opportunities
6 Brazil: Unlocking Potential Growth Opportunities Building on our leadership in-country clinical sales force Expanding SIP through local manufacturing footprint Capitalizing on opportunities for generic injectables and biosimilars Leveraging Brazil to drive future growth in Latin America markets Ou
Slide 83: Agenda
7 Agenda Americas EMEA APAC
Slide 84: EMEA At-A-Glance
8 EMEA At-A-Glance GemStar™ Oxaliplatin Meropenem Key Products Docetaxel Retacrit™ Heparin Paclitaxel Nivestim™ Plum A+™ Irinotecan Gemcitabine CLAVE™ Growth Drivers SIP portfolio expansion Biosimilars MMS in selected markets Emerging markets Cross selling 2010 Sales: $0.5B 2011-2016 Sales CAGR (E):
Slide 85: Strategy: EMEA
9 Strategy: EMEA Expand on-market Hospira products into additional Hospira markets Apply pricing analytics with integrated supply chain Prepare for second-generation US differentiated products Generic Injectables Biosimilars MMS Infrastructure Cross Selling Opportunities Leverage product positions i
Slide 86: EMEA: Portfolio Expansion
10 EMEA: Portfolio Expansion Leverage base: Leverage established positions in countries such as Spain, France, Italy and UK New dedicated business unit structure Drive Go-To-Market Program, which is linked to new business unit structure Portfolio expansion Introduce on-market Hospira products to add
Slide 87: Agenda
11 Agenda Americas EMEA APAC
Slide 88: APAC At-A-Glance
APAC At-A-Glance 12 Growth Drivers Precedex Branded pharmaceuticals Portfolio and channel expansion, especially Japan and China 2010 Sales: $0.3B 5-year Sales CAGR (E): Direct presence: 9 Key markets: Australia, Japan, China, Korea Distributor markets: 9 Key Products Precedex™ Nivestim™ Norepinephri
Slide 89: Strategy: APAC
13 Strategy: APAC Extend #1 SIP position in Australia Leverage clinical selling capabilities to maximize branded pharmaceutical and biosimilar products Create new value for customers by leveraging “vial to vein” portfolio Australia Japan & Korea China Maximize Precedex™ (sales effectiveness and life
Slide 90: Building Expertise in Unique Markets - Japan
14 Building Expertise in Unique Markets – Japan Large market 2nd largest healthcare market Aging population 40% over 65 years by 2050 vs. 23% in 2010 Healthcare funding gap $190B by 2020 Significant inefficiencies opportunity generic penetration 21% average length of hospital stay 14+ days technolog
Slide 91: Building Expertise in Unique Markets - China
15 Building Expertise in Unique Markets – China Fastest growing large injectables market in the world Key driver: Unique emphasis on IV treatment high unmet needs China Injectable Prescription Market ($B)1 33% CAGR 22-24% CAGR 1 Ex manufacturer $65-$75B $21B $9B 2006 2009 2015
Slide 92: Operational Excellence
1 Operational Excellence Jim Hardy
Slide 93: Agenda
2 2 2 Quality improvements Capacity to serve today Inventory as a patch Remediation update Investing in the future Agenda Summary
Slide 94: Quality is Key to Supporting Our Growth
3 3 3 Quality is Key to Supporting Our Growth Ensures regulatory compliance Drives customer satisfaction Drives efficiencies in development of global products Growth Focus on Quality Broad product portfolio in global markets
Slide 95: Repositioning Hospira for Operational Excellence
4 4 4 2004-2006 2007-2010 2011+ Inherited disparate systems Aged facilities New platforms for growth Standardization First-pass quality New leadership Repositioning Hospira for Operational Excellence Spin-off and Transition Acquisition and Integration Operational Excellence
Slide 96: Making Progress in Our Quality Journey
5 5 Making Progress in Our Quality Journey 2010 2011 2012 2013 and beyond Phase 1: Standardization Global quality systems Phase 2: Driving Value In Elevating customer service levels Improved predictive quality processes Phase 3: Staying in Front Continuous improvement culture
Slide 97: Agenda
6 6 6 Quality improvements Capacity to serve today Inventory as a patch Remediation update Investing in the future Agenda Summary
Slide 98: Customer Service Levels Affected by 2010 Challenges
7 7 7 Customer Service Levels Affected by 2010 Challenges Global Customer Service Levels 2009 2010 2011 Customer service levels are measured as products ordered that are filled complete and on time. 80% 84% 88% 92% 96% 100% Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
Slide 99: Addressing the Industry Capacity Challenges
8 8 8 Addressing the Industry Capacity Challenges Competitors going off-market Tightened regulatory expectations Commodity / API supply issues Slower cycle times Aged asset base
Slide 100: Investing in Process, Tools and Equipment
9 9 9 Investing in Process, Tools and Equipment Installed five additional lyophilizers Installed two additional flip-top vial fillers Installed one cartridge-syringe filler Integrated business planning process Statistical safety stock Driving LEAN capabilities Recent Capacity Investments Getting Mor
Slide 101: Agenda
10 10 10 Quality improvements Capacity to serve today Inventory as a patch Remediation update Investing in the future Agenda Summary
Slide 102: Inventory was a Quick Fix for Service Levels
11 11 11 Inventory was a Quick Fix for Service Levels Inventory / Global Customer Service Levels 2009 2010 2011 ($ thousands) Customer Service Levels Inventory Inventory Customer Service Levels $600 $700 $800 $900 $1,000 $1,100 $1,200 Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec 80% 84% 88% 92% 96% 1
Slide 103: New Capabilities Reduce Inventory Without Risk to Service
12 12 New Capabilities will Enable Us to Reduce Inventory Without Risk to Customer Service Statistical safety stock pilot Improved demand planning Enhanced integrated business planning Increased lab capacity 2011 Full implementation of statistical safety stock Vendor managed inventory 2012 Inventory
Slide 104: Agenda
13 13 13 Quality improvements Capacity to serve today Inventory as a patch Remediation update Investing in the future Agenda Summary
Slide 105: Warning Letter Update: Rocky Mount
14 Warning Letter Update: Rocky Mount Subsequent to the June 2011 inspection, the FDA completed another inspection in August, which resulted in additional Form 483 observations that identified further areas for remediation / improvement We are implementing an aggressive remediation plan, including t
Slide 106: Comprehensive MMS Product Review Underway
15 Comprehensive MMS Product Review Underway Comprehensive, risk-based review of all MMS devices underway Complete device portfolio reviews to be completed by end of 2012 Initial reviews focused on Plum™, LifeCare PCA™ and GemStar™ Plum field remediation Expect field remediation to start in 2011 and
Slide 107: Product and Process Remediation Timeline / Cost
16 Product and Process Remediation Timeline / Cost One-time costs are expected to be ~70-75% of total costs Expected remediation timing: Expected cost impact: 2-3 years $200M-$250M
Slide 108: Agenda
17 17 17 Quality improvements Capacity to serve today Inventory as a patch Remediation update Investing in the future Agenda Summary
Slide 109: Transforming Performance Through Our Operations Strategy
18 18 Transforming the Performance of Our Business through Our Operations Strategy Best-in-class product quality and compliance Lowest total landed costs SKU reduction High customer service levels Responsive and flexible manufacturing assets Vision Key Elements Consistent execution, from concept thr
Slide 110: Initiatives to Achieve the Vision
19 19 We have Identified 10 Initiatives to Achieve the Vision Impact within 18 months Quick Strikes Long Burners Major impact within 18 months Increasing impact in 2-5 years Big Bangs Large impact in 3-5 years 5 3 Late-stage customization 7 Direct material reduction 1 Hospira performance system 6 SK
Slide 111: India: Key Strategic Location for Hospira
20 20 3 1 2 India will Serve as a Key Strategic Location for Hospira ZHOPL (JV) Ahmedabad Vizag Greenfield IKKT Chennai Cephalosporins, penicillins and carbapenem antibiotics R&D center of excellence Terminal sterilization and aseptic process manufacturing Significant capacity for future growth Cyto
Slide 112: Significant Benefits to Operating in India
21 21 Significant Benefits to Operating in India Remain a global cost leader in generic injectables Free up capacity in our US facilities to modernize and streamline operations without disrupting supply Compete more effectively in bid/tender markets Leverage experienced and successful team in Chenna
Slide 113: Agenda
22 22 22 Quality improvements Capacity to serve today Inventory as a patch Remediation update Investing in the future Agenda Summary
Slide 114: In Summary: On Track to Deliver Operational Excellence
23 23 IN SUMMARY We are On Track to Deliver Operational Excellence We are fixing our base and preparing the organization for supporting aggressive growth Quality improvement and remediation efforts will position us favorably for long term success We are investing in the future with strategic capacit
Slide 115: Financial Strategy
Financial Strategy Tom Werner, CFO
Slide 116: Key Questions We Will Address Today
2 2 2 Key Questions We Will Address Today How will our expansion initiatives be reflected in net sales and across product categories? Sales Gross margins R&D spend Working capital Capital allocation Can we still get to mid 40 percent adjusted margins? How will we drive expansion and how much comes f
Slide 117: Agenda
3 3 Agenda Sales, margins and earnings Capital allocation
Slide 118: 2016 Financial Goals
4 2016 Financial Goals 5-Year CAGR Mid to high single digits Low to mid teens Net Sales Earnings Per Share* * Earnings Per Share (EPS) is an adjusted; non-GAAP measure.
Slide 119: Strong Sales Growth Outside US
5 Strong Sales Growth Outside US 2011-2016 CAGR Mid single digits Low teens Low to mid teens Americas (includes US) EMEA APAC
Slide 120: Accelerating Sales Growth
6 Accelerating Sales Growth Sales growth accelerates in the latter years as key investments start to show returns 2012E 2013E 2014E 2015E 2016E 2011E Net Sales Mid single-digit growth Low teens growth
Slide 121: Growth Driven by Key Strategic Areas
7 Growth Driven by Key Strategic Areas 2016E 2011E SIP Contract Manufacturing Proprietary Pharma Solutions Biosimilars Medication Management Generic Injectables mid to high single digit 2011-2016 CAGR
Slide 122: Opportunity to Expand Gross Margins
8 Product Mix LEAN Cost Improvement 8 Further Opportunity to Expand Gross Margins 2011E 2016E Quality Improvement Costs Mid to upper 40% * Gross Margin is an adjusted; non-GAAP measure.
Slide 123: Investing in R&D
9 Investing in R&D R&D expense has historically run at approximately 6% of sales R&D profile will increase over the next couple of years to support investment in SIP portfolio expansion Expanding margins will allow for further longer-term R&D investments
Slide 124: Flat SG&A Profile; Improved Mix
10 Flat SG&A Profile; Improved Mix Sales & Marketing Sales & Marketing General & Administration General & Administration Investing in sales and marketing to support growth initiatives, such as biosimilars, while holding the line on G&A 2011E 2016E 14-15% of Sales
Slide 125: Agenda
11 11 Agenda Sales, margins and expenses Capital allocation
Slide 126: Better Efficiency in Working Capital
12 Better Efficiency in Working Capital Significant Improvement Driven by Improved Supply Chain Management and Centralized Purchasing DIOH * DIOH: Days Inventory on Hand. 2012E 2013E 2014E 2015E 2016E 2011E
Slide 127: Investing Capital for Hospira's Future
13 Investing Capital for Hospira’s Future R&D Manufacturing IT India Capacity Expansion New Products / Initiatives Pumps Capital Spending 2011-2016
Slide 128: Poised to Generate Significant Cash Flows
16 Poised to Generate Significant Cash Flows Cash Allocation 2011-2016E Debt Reduction Investments / Milestone Payments Targeted Cash Balance Committed to Share Repurchases Available for Repurchases, M&A Capital Expenditures $4-$5B
Slide 129: Investing Today for Sustainable Long-Term Growth
17 Investing Today for Sustainable Long-Term Growth The next 5 years is characterized by near-term investment We are investing to: capitalize on global revenue growth opportunity expand SIP manufacturing capacity to support future growth drive greater competitive advantage through enhancing our low-
Slide 130: Current Small-Molecule Generic Portfolio by Therapeutic Area
1 Hospira’s Current Small-Molecule Generic Portfolio by Therapeutic Area * LMV (local market value) refers to 2010 annual sales of equivalent products already being sold in the market. LMV is inclusive of the cumulative sales of all companies selling a product in a market where Hospira markets that
Slide 131: Bridge of Previous to New Pipeline Reporting Methodology
2 Bridge of Previous to New Pipeline Reporting Methodology The pipeline comparison uses the pipeline as reported for June 30, 2011. EU5 consists of France, Germany, Italy, Spain, UK; ANZ includes Australia. Previous Pipeline (molecules new to US, EU 5, AU) Additional Concept & Formulation Opportunit